Lina Fine, MD
Psychiatry · Seattle, WANPI 1316107352
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $20,157 of the $29,908 with a category attached, or 67.4%. Harmony Biosciences LLC accounts for 89.1% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $14,787 and has fallen 83.6% since, to $2,423 in 2025. Among psychiatry clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 42 payments — averaging $712.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Harmony Biosciences LLC$27K
- Resmed Corp$2K
- Jazz Pharmaceuticals Inc.$690
- Vertex$387
- Amgen$157
- Idorsia Pharmaceuticals US Inc$108
What the payments were for
- Consulting fees$6,33721%
- Speaking & faculty fees$20,15767%
- Travel & lodging$1,9076%
- Food & beverage$1,5075%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Harmony Biosciences LLC | 31 | $26,641 |
| Resmed Corp | 1 | $1,925 |
| Jazz Pharmaceuticals Inc. | 7 | $690 |
| Vertex | 1 | $387 |
| Amgen | 1 | $157 |
| Idorsia Pharmaceuticals US Inc | 1 | $108 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$29,908 in reported general payments places this provider in the 95th percentile of 576 psychiatry providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 14 | $118,449 |
| FanaptIloperidone | 42 | $82,127 |
| DayvigoLemborexant | 14 | $6,835 |
| Bupropion XlBupropion Hcl | 135 | $6,060 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,724 |
| Lamotrigine | 144 | $3,395 |
| Fluoxetine Hcl | 125 | $2,649 |
| Aripiprazole | 45 | $2,330 |
| Duloxetine Hcl | 63 | $1,605 |
| Buspirone Hcl | 74 | $1,590 |
| Lurasidone Hcl | 15 | $1,489 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 18 | $1,217 |
| Olanzapine | 41 | $1,098 |
| Modafinil | 39 | $1,035 |
| Mirtazapine | 45 | $921 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Seattle
- Chester RobachinskiSeattle$1.1M
- Pablo ProanoSeattle$112K
- Jesse McClellandSeattle$39K
- Jonathan BuchholzSeattle$7K
- Steven MitchellSeattle$7K
- Randall EspinozaSeattle$6K
- John KernSeattle$6K
- James BowenSeattle$4K
- Gerard ZanolliSeattle$3K
- Shahm MartiniSeattle$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.